VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

This is the second COVID-19 vaccine candidate being evaluated at VUMC. A phase 3 clinical trial of an experimental vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) is underway.